pharma
dog
News
when
Latest
Archive
by source
All Sources
Sources Page
Jobs
department
Clinical
Regulatory
Medical Affairs
Commercial
R&D / Discovery
Biostatistics / Data
Manufacturing / CMC
Market Access
therapeutic area
Oncology
Immunology
Neuroscience
Cardiovascular
Metabolic
Rare Disease
Infectious Disease
location & type
Remote Only
US Only
California
Massachusetts
Internships
Phase 3 Roles
All Jobs →
Drugs
by stage
Marketed
Phase 3
Phase 2
Phase 1
Preclinical
browse
Most catalysts
Recently active
All drugs →
Companies
Patent cliff
Calendar
what
Trial readouts
PDUFA dates
Approvals
Earnings
when
Upcoming
Month grid
Recently passed
◐
Sign In
Subscribe
home
jobs
news
search
DAIICHI SANKYO · news · pharmadog
← back to DAIICHI SANKYO
News mentioning DAIICHI SANKYO
36
stories
2d
Summit partners with AstraZeneca and Daiichi; Eccogene earns $50M milestone
endpoints
7d
Merck inks up to $2.13B deal to dine with SciBrunch, gain rights to preclinical KRAS inhibitor
biospace
7d
STAT+: Pharmalittle: We’re reading about GLP-1s becoming lifestyle drugs, a setback for Merck and Daiichi, and more
stat
7d
Merck, Daiichi end plans to seek speedy approval of lung cancer ADC
biopharma dive
7d
Merck, Daiichi Sankyo retract accelerated approval request for lung cancer ADC
biospace
7d
Merck, Daiichi scrap FDA application for B7-H3 ADC in lung cancer
endpoints
7d
Merck, Daiichi pull lung cancer filing after FDA pushback deals another blow to $4B deal
fiercebiotech
21d
Roche, MediLink notch phase 3 lung cancer win but trail GSK on cross-trial survival
fiercebiotech
24d
BioNTech sets survival standard in hard-to-treat cancer ahead of pivotal readout
fiercebiotech
24d
GSK’s Hansoh-partnered ADC lays down marker for lung cancer scrap with Merck
fiercebiotech
Aug 28, 26
Daiichi Sankyo to give commercial team a makeover; Novo Nordisk's GPCR partner finds CMO
endpoints
Aug 28, 26
Genentech doubles down on ADC-resistant cancers with $1B DualityBio pact
fiercebiotech
Aug 27, 26
Chutes & Ladders—Vivace revs up C-suite ahead of pivotal push
fiercebiotech
Aug 26, 26
Jazz scores front-line gastric cancer nod from FDA for ‘practice-changing’ Ziihera
biospace
Aug 10, 26
RevMed, BeOne make clinical trial, Asia deal; MoonLake reports Phase 3 win
endpoints
Aug 6, 26
Context scraps bispecific T-cell engager program to extend cash runway deeper into 2027
fiercebiotech
Aug 3, 26
‘Unlikely’ AstraZeneca-BMS mega-merger would be largest pharma deal ever
biospace
Jul 30, 26
Daiichi’s pipeline falls behind rivals as cash flow nears peak: analysts
biospace
Jul 29, 26
Merck posts—then pulls—trial plan for PD-1xVEGF and TROP2 ADC combination
fiercebiotech
Jul 28, 26
Eli Lilly tops new biopharma ranking on launch success, development speed
fiercebiotech
Jul 28, 26
GSK partner Hansoh reports another phase 3 win for priority ADC
fiercebiotech
Jul 27, 26
AstraZeneca execs ‘very confident’ in homegrown ADC pipeline despite scrapping 2 candidates
fiercebiotech
Jul 21, 26
‘We’ve been looking for a novel approach’: Why Novartis CEO ended ADC holdout for $1.5B Myricx deal
fiercebiotech
Jul 15, 26
Merck ADC, in China study, shows potential to replace chemo in lung cancer
biopharma dive
Jul 8, 26
STAT+: Pharmalittle: We’re reading about a Vera kidney drug approval, a U.K. Enhertu pricing deal, and more
stat
Jul 6, 26
Novartis to acquire ADC developer in a deal worth up to $1.5B
biopharma dive
Jun 26, 26
On second try, Acadia drug gets nod from European regulators
biopharma dive
Jun 4, 26
A Spanish biotech banks $87M to make differentiated ADCs
biopharma dive
May 29, 26
At ASCO, Merck makes case for a ‘cornerstone’ cancer drug
biopharma dive
May 18, 26
Merck ADC, licensed from China, hits mark in first big global trial
biopharma dive
← prev
page 1 of 2
next →
